Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Key Highlights
- ➤David Raben appointed Chief Medical Officer at Pliant Therapeutics (PLRX)
- ➤PLN-101095 key trial readouts targeted for 2027
- ➤575,000 stock options granted to Raben as employment inducement
- ➤PLN-101095 Phase 1b FORTIFY trial enrolls patients with advanced solid tumors
Expert Statements
Bernard Coulie, President and Chief Executive Officer of Pliant Therapeutics
“David’s deep expertise in advancing innovative and targeted oncology therapies, alongside a proven track record of leading programs from early development through regulatory approval, will be important as we advance PLN-101095.”
Bernard Coulie, President and Chief Executive Officer of Pliant Therapeutics
“We look forward to David’s leadership and insight as we progress toward key trial readouts in 2027.”
Leader in targeted immuno-oncology drug development brings three decades of academic and biopharmaceutical oncology expertise
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the appointment of David Raben, M.D., as Chief Medical Officer. Dr. Raben brings more than 30 years of experience in academic translational research, clinical care, and oncology drug development across the biopharmaceutical sector.
Get started
Create a free account to read the full story.